Is Ocugen Inc (OCGN) overvalued? · rev $4.1M
Ocugen Inc (OCGN) is a biotechnology company listed on NASDAQ.
This page asks whether Ocugen Inc (OCGN) looks expensive on cached numbers — not a short thesis.
Latest reported OCGN revenue for 2024-12-31 was $4.1M. Net income was -$54.1M. Revenue was down 32.8% from 2023-12-31 to 2024-12-31. OCGN currently screens at market cap $416.4M.
OCGN currently screens at market cap $416.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next OCGN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the OCGN stock page for the full model, not this heading.
Not investment advice.